scholarly journals DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA

2014 ◽  
Vol 8 (4) ◽  
pp. 1751-1756 ◽  
Author(s):  
HONGNA LU ◽  
SHILIANG HUANG ◽  
XIE ZHANG ◽  
DANPING WANG ◽  
XUESONG ZHANG ◽  
...  
2014 ◽  
Vol 22 (22) ◽  
pp. 3201
Author(s):  
Hu Zhang ◽  
You-Qing Zhu ◽  
Ya-Qiong Wu ◽  
Ping Zhang ◽  
Jun Jiang ◽  
...  

2021 ◽  
Vol 43 (3) ◽  
pp. 1419-1435
Author(s):  
Walter Pulverer ◽  
Kristi Kruusmaa ◽  
Silvia Schönthaler ◽  
Jasmin Huber ◽  
Marko Bitenc ◽  
...  

Early diagnosis of colorectal cancer (CRC) is of high importance as prognosis depends on tumour stage at the time of diagnosis. Detection of tumour-specific DNA methylation marks in cfDNA has several advantages over other approaches and has great potential for solving diagnostic needs. We report here the identification of DNA methylation biomarkers for CRC and give insights in our methylation-sensitive restriction enzyme coupled qPCR (MSRE-qPCR) system. Targeted microarrays were used to investigate the DNA methylation status of 360 cancer-associated genes. Validation was done by qPCR-based approaches. A focus was on investigating marker performance in cfDNA from 88 patients (44 CRC, 44 controls). Finally, the workflow was scaled-up to perform 180plex analysis on 110 cfDNA samples, to identify a DNA methylation signature for advanced colonic adenomas (AA). A DNA methylation signature (n = 44) was deduced from microarray experiments and confirmed by quantitative methylation-specific PCR (qMSP) and by MSRE-qPCR, providing for six genes’ single areas under the curve (AUC) values of >0.85 (WT1, PENK, SPARC, GDNF, TMEFF2, DCC). A subset of the signatures can be used for patient stratification and therapy monitoring for progressed CRC with liver metastasis using cfDNA. Furthermore, we identified a 35-plex classifier for the identification of AAs with an AUC of 0.80.


2018 ◽  
Vol 43 (1) ◽  
pp. 176-188 ◽  
Author(s):  
Ana B. Crujeiras ◽  
Sonsoles Morcillo ◽  
Angel Diaz-Lagares ◽  
Juan Sandoval ◽  
Daniel Castellano-Castillo ◽  
...  

2014 ◽  
Vol 53 (7) ◽  
pp. 537-548 ◽  
Author(s):  
Troy D. Dumenil ◽  
Leesa F. Wockner ◽  
Mark Bettington ◽  
Diane M. McKeone ◽  
Kerenaftali Klein ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
S. Bach ◽  
I. Paulis ◽  
N. R. Sluiter ◽  
M. Tibbesma ◽  
I. Martin ◽  
...  

AbstractColorectal cancer (CRC) is the second leading cause for cancer-related death globally. Clinically, there is an urgent need for non-invasive CRC detection. This study assessed the feasibility of CRC detection by analysis of tumor-derived methylated DNA fragments in urine. Urine samples, including both unfractioned and supernatant urine fractions, of 92 CRC patients and 63 healthy volunteers were analyzed for DNA methylation levels of 6 CRC-associated markers (SEPT9, TMEFF2, SDC2, NDRG4, VIM and ALX4). Optimal marker panels were determined by two statistical approaches. Methylation levels of SEPT9 were significantly increased in urine supernatant of CRC patients compared to controls (p < 0.0001). Methylation analysis in unfractioned urine appeared inaccurate. Following multivariate logistic regression and classification and regression tree analysis, a marker panel consisting of SEPT9 and SDC2 was able to detect up to 70% of CRC cases in urine supernatant at 86% specificity. First evidence is provided for CRC detection in urine by SEPT9 methylation analysis, which combined with SDC2 allows for an optimal differentiation between CRC patients and controls. Urine therefore provides a promising liquid biopsy for non-invasive CRC detection.


Sign in / Sign up

Export Citation Format

Share Document